AGI 101H

Drug Profile

AGI 101H

Alternative Names: AGI-101

Latest Information Update: 10 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AGIRx
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 10 Sep 2018 Discontinued - Phase-II for Malignant melanoma (Inoperable/Unresectable, Late-stage disease) in Poland (Parenteral)
  • 10 Sep 2018 Discontinued - Phase-II for Malignant melanoma (Late-stage disease, Adjuvant therapy) in Poland (Parenteral)
  • 21 Apr 2016 AGIRx terminates a phase I/II trial in Malignant melanoma in Poland (NCT00716495)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top